Uncover key drivers, emerging technologies, and competitive movements shaping the non-viral gene delivery technologies market from 2025–2034 with trusted insights from The Business Research Company

How Will The Non-Viral Gene Delivery Technologies Market Valuation Change Between Now And 2029?

The market for non-viral gene delivery technologies has experienced significant expansion recently. This market is projected to expand from $3.96 billion in 2024 to $4.57 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 15.6%. Historically, this growth has been driven by factors such as the broadening of genetic research, the increasing occurrence of chronic genetic disorders, expanding biotechnology and pharmaceutical research and development (R&D) activities, advancements in genetic and molecular biology research, and enhanced financial backing from government bodies and institutions.

The non-viral gene delivery technologies market is projected for substantial expansion in the coming years, anticipated to reach $8.06 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.2%. This anticipated growth is largely driven by factors such as the increasing need for personalized medicine, wider utilization in cancer and rare disease investigations, the emergence of clustered regularly interspaced short palindromic repeats and gene editing technologies, swift advancements in mRNA-based treatments, and the expansion of cell therapy and tissue engineering applications. Significant developments expected during this period encompass enhancements in lipid nanoparticles and polymer-based delivery systems, the creation of deoxyribonucleic acid and ribonucleic acid therapeutics, incorporation of artificial intelligence and computational modeling, the introduction of next-generation lipid nanoparticles (LNPs), and progress in nanotechnology.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27367&type=smp

What Growth-Enabling Forces Are Impacting The Non-Viral Gene Delivery Technologies Market?

The rising need for personalized medicine is anticipated to propel the future growth of the non-viral gene delivery technologies market. This medical strategy customizes prevention, diagnosis, and treatment based on an individual’s unique genetic makeup, lifestyle, and environmental factors. The escalating demand for personalized medicine is driven by advancements in genomic sequencing technologies, which enable more accurate diagnoses, targeted therapies, and improved treatment outcomes tailored to individual patients. This growing emphasis on personalized medicine fuels the demand for non-viral gene delivery technologies, as they offer safer and more adaptable methods to deliver therapeutic genes customized to an individual’s genetic profile, without the risks associated with viral vectors. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, a considerable increase compared to 6 in 2022. Therefore, the expanding demand for personalized medicine is a primary driver for the growth of the non-viral gene delivery technologies market.

What Are The Main Segment Classifications In The Non-Viral Gene Delivery Technologies Market?

The non-viral gene delivery technologies market covered in this report is segmented

1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles

2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo

3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles

4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression

5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses

Subsegments:

1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents

2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems

3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles

How Are Industry Trends Steering The Expansion Of The Non-Viral Gene Delivery Technologies Market?

Leading companies within the non-viral gene delivery market are concentrating on developing advanced solutions like non-viral genetic medicine platforms to improve the safety and efficiency of gene therapies. A non-viral genetic medicine platform is a technology that introduces therapeutic genes or nucleic acids into cells without the use of viruses, thereby reducing immune reactions and safety concerns, and enabling precise and controlled gene therapy delivery for a multitude of diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company focused on developing genetic medicines, unveiled immune-quiet DNA (iqDNA). This novel DNA is an optimized version of their closed-ended DNA (ceDNA) which evades innate immune detection, exhibiting cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered via their lipid nanoparticle (LNP) system. Due to iqDNA’s superior tolerability, Generation Bio is advancing this as the primary DNA cargo in all its initiatives, including its lead program for hemophilia A.

Which Firms Are Driving Innovation Within The Non-Viral Gene Delivery Technologies Market?

Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Boehringer Ingelheim GmbH, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Bio-Rad Laboratories Inc., Bio-Techne Corp., Takara Bio Inc., GenScript Biotech Corporation, Poseida Therapeutics Inc., ElevateBio LLC, ProBio Inc., ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/non-viral-gene-delivery-technologies-global-market-report

What Are The Emerging Regional Trends Driving The Non-Viral Gene Delivery Technologies Market?

North America was the largest region in the non-viral gene delivery technologies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27367&type=smp

Browse Through More Reports Similar to the Global Non-Viral Gene Delivery Technologies Market 2025, By The Business Research Company

Low Density Polyethylene Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/low-density-polyethylene-global-market-report

High Density Polyethylene Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/high-density-polyethylene-global-market-report

Polyethylene Terephthalate Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/polyethylene-terephthalate-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model